Indaptus Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Indaptus Therapeutics Stock-Based Compensation Growth & History (INDP)
Indaptus Therapeutics's stock-based compensation was $1.4M for fiscal 2025.
View full Indaptus Therapeutics company overviewIndaptus Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | −$947,767 | −41.10% |
| 2024 | 2024-12-31 | $2.3M | −$660,089 | −22.26% |
| 2023 | 2023-12-31 | $3.0M | $8,689 | +0.29% |
| 2022 | 2022-12-31 | $3.0M | $1.4M | +95.81% |
| 2021 | 2021-12-31 | $1.5M | $1.4M | +979.06% |
| 2020 | 2020-12-31 | $139,960 | — | — |
Indaptus Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$64,283 | −$245,046 | — |
| Q1 2026 | 2026-03-31 | $227,180 | −$13,711 | −5.69% |
| Q4 2025 | 2025-12-31 | $785,814 | $481,692 | +158.39% |
| Q3 2025 | 2025-09-30 | $150,614 | −$293,570 | −66.09% |
| Q2 2025 | 2025-06-30 | $180,763 | −$602,089 | −76.91% |
| Q1 2025 | 2025-03-31 | $240,891 | −$533,800 | −68.90% |
| Q4 2024 | 2024-12-31 | $304,122 | −$441,403 | −59.21% |
| Q3 2024 | 2024-09-30 | $444,184 | −$320,619 | −41.92% |
| Q2 2024 | 2024-06-30 | $782,852 | $54,386 | +7.47% |
| Q1 2024 | 2024-03-31 | $774,691 | $47,547 | +6.54% |
| Q4 2023 | 2023-12-31 | $745,525 | $107,895 | +16.92% |
| Q3 2023 | 2023-09-30 | $764,803 | $180,762 | +30.95% |
| Q2 2023 | 2023-06-30 | $728,466 | −$175,929 | −19.45% |
| Q1 2023 | 2023-03-31 | $727,144 | −$104,039 | −12.52% |
| Q4 2022 | 2022-12-31 | $637,630 | −$36,172 | −5.37% |
| Q3 2022 | 2022-09-30 | $584,041 | −$211,297 | −26.57% |
| Q2 2022 | 2022-06-30 | $904,395 | $883,722 | +4274.76% |
| Q1 2022 | 2022-03-31 | $831,183 | $810,738 | +3965.46% |
| Q4 2021 | 2021-12-31 | $673,802 | — | — |
| Q3 2021 | 2021-09-30 | $795,338 | $756,130 | +1928.51% |
| Q2 2021 | 2021-06-30 | $20,673 | −$393,327 | −95.01% |
| Q1 2021 | 2021-03-31 | $20,445 | — | — |
| Q3 2020 | 2020-09-30 | $39,208 | — | — |
| Q2 2020 | 2020-06-30 | $414,000 | — | — |
Indaptus Therapeutics stock-based compensation trends
Over the last five fiscal years, Indaptus Therapeutics's stock-based compensation increased from $139,960 to $1.4M, a change of $1.2M. The latest reported quarter, Q2 2026, shows −$64,283.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indaptus Therapeutics source filings ↗